Abstract β-Hydroxybutyrate (β-HB), the primary circulating ketone body, plays a dual role as
both a metabolic fuel and an endogenous signaling molecule, offering diverse systemic …

Cisplatin is a particularly potent antineoplastic drug. However, its usefulness is restricted
due to the induction of nephrotoxicity. More recent research has indicated that β …

Cisplatin, as a commonly used anticancer drug, can easily lead to acute kidney injury (AKI),
and has received more and more attention in clinical practice. β-hydroxybutyric acid (BHB) is …

Background Sepsis is a major cause of acute kidney injury (AKI). Recent studies have
demonstrated that β-hydroxybutyrate (β-HB) alleviates renal ischemia-reperfusion injury and …

Gamma-aminobutyric acid (GABA) is one of the inhibitory neurotransmitters. Several studies
have suggested that GABA supplements can reduce blood pressure and modulate the renal …

Cisplatin (CP) treatment has been long associated with the development of acute kidney
injury (AKI) through mechanisms involving inflammation and oxidative stress. α-Bisabolol …

Ketone bodies including β-hydroxybutyrate (β-OHB) have been shown to protect against
ischemic tissue injury when present at low concentrations. We evaluated the impact of β …

Cisplatin is one of the most potent chemotherapeutic antitumor drugs used in the treatment
of a wide range of solid tumors. Its primary dose-limiting side effect is nephrotoxicity. This …

Acute renal failure is a serious complication of the anticancer drug cisplatin. The potential
role of baicalein, a naturally occurring bioflavonoid on cisplatin-induced renal injury is …

Cisplatin is an effective chemotherapeutic agent, but its clinical use is frequently limited by
its nephrotoxicity. The pathogenesis of cisplatin-induced acute kidney injury (AKI) remains …